---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002135"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:12:16.149448+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027

## Summary
- AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.
- Phase 3 RAMP 301 trial fully accrued; topline PFS data expected mid-2027.
- VS-7375 KRAS G12D inhibitor: cleared 900 mg QD dose no DLTs; FDA FTD in PDAC.
- Pipeline milestones: RAMP 205 update 1H2026; VS-7375 monotherapy expansion cohorts 1H2026.
- Extended cash runway into 1H2027 via Oberland debt refinancing and equity investment.

## SEC filing metadata
- accession: 0001104659-26-002135
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/0001104659-26-002135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/tm262531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002135
- JSON: https://secwatch.observer/filing/0001104659-26-002135.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.